Last updated on February 2018

Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF

Brief description of study

The study will assess the safety of different dose regimens of HepaStem in cirrhotic Patients with ACLF or with acute decompensation at risk of developing ACLF up to Day 28 of the active study period.

Clinical Study Identifier: NCT02946554

Contact Investigators or Research Sites near you

Start Over

Thierry Gustot, MD

H pital Erasme
Brussels, Belgium
  Connect »

Sven Francque, MD

UZ Antwerpen
Edegem, Belgium
  Connect »

Frederik Nevens, MD

KU Leuven
Leuven, Belgium
  Connect »

Pierre-Francois Laterre, MD

Cliniques St Luc
Woluwe-Saint Lambert, Belgium
  Connect »

Francois Durand, MD

H pital Beaujon
Clichy, France
  Connect »

Fabien Zoulim, MD

H pital de la Croix Rousse
Lyon, France
  Connect »

Didier Samuel, MD

H pital Paul Brousse
Villejuif, France
  Connect »

Luc Lasser, MD

CHU Brugmann
Bruxelles, Belgium
  Connect »

Olivier DETRY, MD

CHU de Li ge
Liège, Belgium
  Connect »